ERBB2 and breast carcinoma: Since the miR-1296-5p inhibits cell proliferation of breast cancer cell line, a hypothesis is proposed that miR-1296-5p might evoke the apoptosis of ERBB2-positive breast cancer cells by weakening drug resistance.